Literature DB >> 19609950

Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Renyuan Zhou1, Reneé Shanas, Mark A Nelson, Achyut Bhattacharyya, Jiaqi Shi.   

Abstract

The heterogeneous nuclear ribonucleoprotein (hnRNP) K is an essential RNA and DNA binding protein involved in gene expression and signal transduction including DNA transcription, RNA splicing, RNA stability and translation. The role of hnRNP K in cancer is relatively understudied. However, several cellular functions strongly indicate that hnRNP K is involved in tumorigenesis. In this study, we investigated the altered protein expression and the subcellular distribution of the hnRNP K protein using tissue microarrays in pancreatic cancer. We showed an increased cytoplasmic hnRNP K in pancreatic cancer. This increase in hnRNP K protein occurs at the posttranscriptional level. We postulate that the cytoplasmic accumulation of hnRNP K will lead to silenced mRNA translation of tumor suppressor genes and thus contributes to pancreatic cancer development. We also demonstrated that knocking down of hnRNP K expression by siRNA inhibited pancreatic cancer cell growth and colony formation. hnRNP K was identified as a member of the p53/HDM2 pathway. Whether hnRNP K interacts with the mutant p53 is not known. Using two different pancreatic cancer cell lines, we can demonstrate that hnRNP K interacts with the mutant p53. The subcellular distribution and function of the mutant p53 and the interaction of hnRNP K/mutant p53 were affected by the Ras/MEK/ERK pathway, growth factors and the specific p53 mutations in pancreatic cancer cells. Since Kras is activated and p53 is mutated in most pancreatic cancers, these data unveiled an important new signaling pathway that linked by hnRNP K and mutant p53 in pancreatic cancer tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19609950      PMCID: PMC2795109          DOI: 10.1002/ijc.24744

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

Review 1.  Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.

Authors:  Renata Talar-Wojnarowska; Ewa Malecka-Panas
Journal:  Med Sci Monit       Date:  2006-09

2.  ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation.

Authors:  H Habelhah; K Shah; L Huang; A Ostareck-Lederer; A L Burlingame; K M Shokat; M W Hentze; Z Ronai
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

3.  Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue.

Authors:  B C Blaxall; L D Dwyer-Nield; A K Bauer; T J Bohlmeyer; A M Malkinson; J D Port
Journal:  Mol Carcinog       Date:  2000-06       Impact factor: 4.784

Review 4.  Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage.

Authors:  D A Gewirtz
Journal:  Breast Cancer Res Treat       Date:  2000-08       Impact factor: 4.872

5.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype.

Authors:  H Ouyang; Lj Mou; C Luk; N Liu; J Karaskova; J Squire; M S Tsao
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

6.  Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function.

Authors:  M Mandal; R Vadlamudi; D Nguyen; R A Wang; L Costa; R Bagheri-Yarmand; J Mendelsohn; R Kumar
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

7.  Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.

Authors:  W T Loging; D Reisman
Journal:  Oncogene       Date:  1999-12-09       Impact factor: 9.867

Review 8.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

9.  MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.

Authors:  Martin Enge; Wenjie Bao; Elisabeth Hedström; Stephen P Jackson; Abdeladim Moumen; Galina Selivanova
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.

Authors:  Durga Prasad Cherukuri; Xiao B O Chen; Anne-Christine Goulet; Robert N Young; Yongxin Han; Ronald L Heimark; John W Regan; Emmanuelle Meuillet; Mark A Nelson
Journal:  Exp Cell Res       Date:  2007-06-22       Impact factor: 3.905

View more
  27 in total

1.  Intrinsic apoptotic pathway and G2/M cell cycle arrest involved in tubeimoside I-induced EC109 cell death.

Authors:  Yang Xu; Guanghui Wang; Quancheng Chen; Ting Lin; Zhiping Zeng; Qiang Luo; Jie Liu; Cuiling Sun
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

2.  Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma.

Authors:  Fushi Wen; Alex Shen; Reneé Shanas; Achyut Bhattacharyya; Fangru Lian; Galen Hostetter; Jiaqi Shi
Journal:  Ann Surg Oncol       Date:  2010-05-25       Impact factor: 5.344

3.  hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

Authors:  Miguel Gallardo; Hun Ju Lee; Xiaorui Zhang; Carlos Bueso-Ramos; Laura R Pageon; Mark McArthur; Asha Multani; Aziz Nazha; Taghi Manshouri; Jan Parker-Thornburg; Inmaculada Rapado; Alfonso Quintas-Cardama; Steven M Kornblau; Joaquin Martinez-Lopez; Sean M Post
Journal:  Cancer Cell       Date:  2015-09-24       Impact factor: 31.743

4.  Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis.

Authors:  Ran Gao; Yue Yu; Atsushi Inoue; Nashi Widodo; Sunil C Kaul; Renu Wadhwa
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

Review 5.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

6.  All human granzymes target hnRNP K that is essential for tumor cell viability.

Authors:  Robert van Domselaar; Razi Quadir; Astrid M van der Made; Roel Broekhuizen; Niels Bovenschen
Journal:  J Biol Chem       Date:  2012-05-11       Impact factor: 5.157

7.  Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.

Authors:  Yantong Guo; Jingming Zhao; Jingtao Bi; Quan Wu; Xin Wang; Quanyou Lai
Journal:  J Hematol Oncol       Date:  2012-07-03       Impact factor: 17.388

8.  C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress.

Authors:  Jodi Meyerowitz; Sarah J Parker; Laura J Vella; Dominic Ch Ng; Katherine A Price; Jeffrey R Liddell; Aphrodite Caragounis; Qiao-Xin Li; Colin L Masters; Takashi Nonaka; Masato Hasegawa; Marie A Bogoyevitch; Katja M Kanninen; Peter J Crouch; Anthony R White
Journal:  Mol Neurodegener       Date:  2011-08-08       Impact factor: 14.195

9.  HMGA1a recognition candidate DNA sequences in humans.

Authors:  Takayuki Manabe; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress.

Authors:  Diane Moujalled; Janine L James; Sarah J Parker; Grace E Lidgerwood; Clare Duncan; Jodi Meyerowitz; Takashi Nonaka; Masato Hasegawa; Katja M Kanninen; Alexandra Grubman; Jeffrey R Liddell; Peter J Crouch; Anthony R White
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.